1. Home
  2. PCLA vs SCYX Comparison

PCLA vs SCYX Comparison

Compare PCLA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCLA
  • SCYX
  • Stock Information
  • Founded
  • PCLA 2008
  • SCYX 1999
  • Country
  • PCLA Japan
  • SCYX United States
  • Employees
  • PCLA N/A
  • SCYX N/A
  • Industry
  • PCLA Building Products
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCLA Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • PCLA Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • PCLA 71.3M
  • SCYX 28.5M
  • IPO Year
  • PCLA 2025
  • SCYX 2014
  • Fundamental
  • Price
  • PCLA $0.88
  • SCYX $0.72
  • Analyst Decision
  • PCLA
  • SCYX
  • Analyst Count
  • PCLA 0
  • SCYX 0
  • Target Price
  • PCLA N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • PCLA 3.7M
  • SCYX 200.7K
  • Earning Date
  • PCLA 01-01-0001
  • SCYX 08-07-2025
  • Dividend Yield
  • PCLA N/A
  • SCYX N/A
  • EPS Growth
  • PCLA N/A
  • SCYX N/A
  • EPS
  • PCLA N/A
  • SCYX N/A
  • Revenue
  • PCLA $5,475,228.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • PCLA N/A
  • SCYX $410.22
  • Revenue Next Year
  • PCLA N/A
  • SCYX $248.83
  • P/E Ratio
  • PCLA N/A
  • SCYX N/A
  • Revenue Growth
  • PCLA 40.19
  • SCYX N/A
  • 52 Week Low
  • PCLA $0.37
  • SCYX $0.66
  • 52 Week High
  • PCLA $9.80
  • SCYX $2.28
  • Technical
  • Relative Strength Index (RSI)
  • PCLA N/A
  • SCYX 46.77
  • Support Level
  • PCLA N/A
  • SCYX $0.67
  • Resistance Level
  • PCLA N/A
  • SCYX $0.83
  • Average True Range (ATR)
  • PCLA 0.00
  • SCYX 0.05
  • MACD
  • PCLA 0.00
  • SCYX 0.01
  • Stochastic Oscillator
  • PCLA 0.00
  • SCYX 46.35

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: